Download PDF
Z Gastroenterol 2010; 48(1): 46-55
DOI: 10.1055/s-0028-1109980
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

ALT als Screeningparameter für Lebererkrankungen: eine kritische Evaluation der Evidenz

ALT Screening for Chronic Liver Diseases: Scrutinizing the EvidenceH. Wedemeyer1 , W. P. Hofmann2 , S. Lueth3 , P. Malinski1 , R. Thimme4 , F. Tacke5 , J. Wiegand6
  • 1Klinik für Gastroenterologie, Hepatologie and Endokrinologie, Medizinische Hochschule Hannover
  • 2Medizinische Klinik 1, Klinikum der J.-W.-Goethe-Universität
  • 3Medizinische Klinik, UKE
  • 4Abteilung Innere Medizin II, Medizinische Universitätsklinik Freiburg
  • 5Medizinische Klinik III, Universitätsklinikum Aachen
  • 6Department für Innere Medizin, Dermatologie und Neurologie, Klinik für Gastroenterologie und Rheumatologie, Universität Leipzig
Further Information

Publication History

Manuskript eingetroffen: 9.11.2009

Manuskript akzeptiert: 7.12.2009

Publication Date:
13 January 2010 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Erhöhte Serum-Aminotransferasen können eine Leberschädigung anzeigen. Dementsprechend wird im Rahmen von Screeninguntersuchungen bei Verdacht auf Lebererkrankungen eine Bestimmung der Aspartat-Aminotransferase (AST) und Alanin-Aminotransferase (ALT) durchgeführt. Ziel der vorliegenden Arbeit ist es, die Evidenz für ALT-Bestimmungen als Screeningtest für Leberkrankungen kritisch zu hinterfragen. Zusammenfassend stellen wir fest, dass 1. erhöhte Serum-ALT-Werte mit hoher Spezifität und guter Sensitivität Lebererkrankungen anzeigen, 2. 10 – 25 % der erwachsenen deutschen Bevölkerung erhöhte ALT-Werte aufweisen, 3. ALT-Werte bei vielen, aber nicht bei allen Patienten mit Lebererkrankungen erhöht sind, 4. erhöhte ALT-Werte mit einer erhöhten leberspezifischen Mortalität assoziiert sind, 5. erhöhte ALT Werte auch als Risikofaktor für primär nicht hepatische Erkrankungen wie Diabetes Mellitus Typ 2, metabolisches Syndrom, kardiovaskuläre Erkrankungen und Tumorerkrankungen angesehen werden müssen, 6. für viele Lebererkrankungen, die mit einem ALT-Screening identifiziert werden, effiziente Therapien vorliegen, die klinische Endpunkte verhindern können, 7. ALT-Testungen wahrscheinlich kosteneffektiv sind, wobei hier allerdings weitere Studien für Deutschland notwendig sind.

Abstract

Elevated serum amino-transferase levels may be associated with liver injury. Testing for aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is part of many routine screening approaches. The aim of this manuscript was to scrutinize the evidence for using ALT testing as a primary screening parameter for liver diseases. We conclude that (i) elevated serum ALT levels indicate a high specificity and a reasonable sensitivity liver injury, (ii) 10 – 25 % of German adults have elevated ALT levels, (iii) ALT values are increased in the majority but not all patients with acute and chronic liver disease (iv) elevated ALT-values are associated with an increased risk of liver-specific mortality, (v) elevated ALT values are also a risk factor for non-hepatic diseases including diabetes mellitus type 2, metabolic syndrome, cardiovascular diseases and malignancies, (vi) many liver diseases identified by an ALT screening can be treated successfully including prevention of development of clinical endpoints, (vii) an ALT-screening is very likely to be cost-effective although studies are needed for Germany to support this conclusion.

Schlüsselwörter

Leber - Virushepatitis - Autoimmunhepatitis

Key words

liver - viral hepatitis - autoimmune hepatitis

Literatur

  • 1 Craxi A, Almasio P. Diagnostic approach to liver enzyme elevation.  J Hepatol. 1996;  25 (Suppl 1) 47-51
    Google Scholar
  • 2 Kew M C. Serum aminotransferase concentration as evidence of hepatocellular damage.  Lancet. 2000;  355 (9204) 591-592
    Google Scholar
  • 3 Stasia M J. et al . Aspartate aminotransferase macroenzyme complex in serum identified and characterized.  Clin Chem. 1994;  40 (7 Pt 1) 1340-1343
    Google Scholar
  • 4 Sonntag O. Hemolysis as interference factor in clinical chemistry.  J Clin Chem Clin Biochem. 1986;  24 127-139
    Google Scholar
  • 5 Heins M, Heil W, Withold W. Storage of Serum or whole blood samples? Effects of time and temperature on 22 serum analytes.  Eur J Clin Chem Clin Biochem. 1995;  33 231-238
    Google Scholar
  • 6 Park G J. et al . Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis?.  J Gastroenterol Hepatol. 2000;  15 (4) 386-390
    Google Scholar
  • 7 Kuntz H D, May B. Quantitative liver function diagnosis.  MMW Munch Med Wochenschr. 1983;  125 (29 – 30) 678-680
    Google Scholar
  • 8 Schmidt E SF. Diagnostik des Ikterus.  Dtsch Med Wochenschr. 1984;  109 139-144
    Google Scholar
  • 9 Elinav E. et al . Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern.  Am J Gastroenterol. 2005;  100 (10) 2201-2204
    Google Scholar
  • 10 Zeuzem S. et al . Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.  Gastroenterology. 2004;  127 (6) 1724-1732
    Google Scholar
  • 11 Baumeister S EVH, Marschall P. et al . Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation.  Gastroenterology. 2008;  134 85-94
    Google Scholar
  • 12 Arndt V BH, Rothenbacher D, Zschenderlein B. et al . Elevated liver enzyme activity in construction workers: prevalence and impact on early retirement and all-cause mortality.  Int Arch Occup Environ Health. 1998;  71 (6) 405-412
    Google Scholar
  • 13 Wiegand J KT, Lobstein S, Brand F. et al . Low prevalence of chronic hepatitis C, but high prevalence of elevated aminotransferases in a cohort of 2026 patients referred for orthopaedic surgery in the eastern part of Germany.  Z Gastroenterol. 2006;  44 (1) 11-14
    Google Scholar
  • 14 Lobstein S KT, Liebert U, Wojan M. et al . Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a german cohort of orthopaedic surgery patients.  Z Gastroenterol. 2008;  46 (5) 415-420
    Google Scholar
  • 15 Papatheodoridis G VGJ, Christodoulou D, Manolakopoulos S. et al . High prevalence of elevated liver enzymes in blood donors: associations with male gender and central adiposity.  Eur J Gastroenterol Hepatol. 2007;  19 (4) 281-287
    Google Scholar
  • 16 Kim H CNC, Jee S H, Han K H. et al . Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study.  BMJ. 2004;  328 (7446) 983
    Google Scholar
  • 17 Ruhl C EEJ. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.  Gastroenterology. 2003;  124 (1) 71-79
    Google Scholar
  • 18 Ruhl C EEJ. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population.  Gastroenterology. 2009;  136 477-485
    Google Scholar
  • 19 Fraser A LM, Lawlor D A. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999 – 2004.  Gastroenterology. 2007;  133 (6) 1814-1820
    Google Scholar
  • 20 Vliet van M, Rosenstiel I A, Schindhelm R K. et al . The association of elevated alanine aminotransferase and the metabolic syndrome in an overweight and obese pediatric population of multi-ethnic origin.  Eur J Pediatr. 2009;  168 (5) 585-591
    Google Scholar
  • 21 McMahon von B. The natural history of chronic hepatitis B virus infection.  Hepatology. 2009;  49 45-55
    Google Scholar
  • 22 Cornberg M PU, Dollinger M M. et al . Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection.  Z Gastroenterol. 2007;  45 1281-1328
    Google Scholar
  • 23 Fattovich G ON, Pasino M. et al . Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years.  Gut. 2008;  57 84-90
    Google Scholar
  • 24 Assy N BZ, Djibre A. et al . Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from inactive chronic carriers.  World J Gastroenterol. 2009;  15 3025-3031
    Google Scholar
  • 25 Chiang J CLC, Wang J H. et al . Identifying hepatitis C virus: endemic areas and estimating the viral antibody prevalence based on the prevalence of ALT elevation.  Trans R Soc Trop Med Hyg. 2009;  103 917-923
    Google Scholar
  • 26 Schlosser B DD, Möckel M. et al . Ist ein generelles Hepatitis C Screening sinnvoll? Anti-HCV Prävalenz bei 13.832 konsekutiven Patienten einer internistischen und chirurgisch-traumatologischen Notaufnahme.  Z Gastroenterol. 2009;  47 961
    Google Scholar
  • 27 Wiese M BF, Lafrenz M, Porst H. et al . Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study.  Hepatology. 2000;  32 91-96
    Google Scholar
  • 28 Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.  N Engl J Med. 1999;  340 1228-1233
    Google Scholar
  • 29 Clark J. The epidemiology of nonalcoholic fatty liver disease in adults.  J Clin Gastroenterol. 2006;  40 (Suppl 1) S5-S10
    Google Scholar
  • 30 Bacon B RFM, Janney C G, Neuschwander-Tetri B A. Nonalcoholic steatohepatitis: an expanded clinical entity.  Gastroenterology. 1994;  107 1103-1109
    Google Scholar
  • 31 Argo C KNP, Al-Osaimi A M, Caldwell S H. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis.  J Hepatol. 2009;  51 371-379
    Google Scholar
  • 32 Luth S HJ, Kanzler S. et al . Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis.  J Clin Gastroenterol. 2008;  42 926-930
    Google Scholar
  • 33 Feld J JDH, Arenovich T. et al . Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome.  Hepatology. 2005;  42 53-62
    Google Scholar
  • 34 Alempijevic T KM, Jesic R. et al . Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis.  World J Gastroenterol. 2009;  15 591-594
    Google Scholar
  • 35 Twaddell W SLJ, Berk P D. Evolution from primary biliary cirrhosis to primary biliary cirrhosis/autoimmune hepatitis overlap syndrome.  Semin Liver Dis. 2008;  28 128-134
    Google Scholar
  • 36 Tischendorf J JHH, Kruger M, Manns M P. et al . Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study.  Am J Gastroenterol. 2007;  102 107-114
    Google Scholar
  • 37 Stremmel W NC, Strohmeyer G. Diagnose der primären Hämochromatose.  Dtsch Med Wochenschr. 1993;  118 227-229
    Google Scholar
  • 38 Beaton M AP. Assessment of silent liver fibrosis in hemochromatosis C 282Y homozygotes with normal transaminase levels.  Clin Gastroenterol Hepatol. 2008;  6 713-714
    Google Scholar
  • 39 Korman J DVI, Balko J. et al . Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests.  Hepatology. 2008;  48 1167-1174
    Google Scholar
  • 40 Betro M GOR, Edwards J B. Gamma-glutamyl transpeptidase and other liver function tests in myocardial infarction and heart failure.  Am J Clin Pathol. 1973;  60 679-683
    Google Scholar
  • 41 Ruhl C EEJ. Epidemiology of nonalcoholic fatty liver.  Clin Liver Dis. 2004;  8 501-519
    Google Scholar
  • 42 Perry I JWS, Shaper A G. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM.  Diabetes Care. 1998;  21 732-737
    Google Scholar
  • 43 Vozarova B SN, Lindsay R S, Saremi A. et al . High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes.  Diabetes. 2002;  51 1889-1895
    Google Scholar
  • 44 Goessling W MJ, Vasan R S. et al . Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease.  Gastroenterology. 2008;  135 1935-1944
    Google Scholar
  • 45 Sato K KHT, Nakamura Y, Harita N. et al . Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai Healthcare Study.  Diabetes Care. 2008;  31 1230-1236
    Google Scholar
  • 46 Wannamethee S GSA, Lennon L, Whincup P H. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men.  Diabetes Care. 2005;  28 2913-2918
    Google Scholar
  • 47 Ford E SSM, Bergmann M M, Thamer C. et al . Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study.  Diabetes Care. 2008;  31 1138-1143
    Google Scholar
  • 48 Fraser A HR, Sattar N, Ebrahim S. et al . Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis.  Diabetes Care. 2009;  32 741-750
    Google Scholar
  • 49 Andre P BB, Vol S, Charles M A. et al . Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort.  Diabetes Care. 2007;  30 2355-2361
    Google Scholar
  • 50 Schindhelm R KDJ, Nijpels G, Bouter L M. et al . Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study.  Atherosclerosis. 2007;  191 391-396
    Google Scholar
  • 51 Monami M BD, Lamanna C, Melani C. et al . Prognostic value of serum liver enzymes levels in type 2 diabetic patients.  Diabetes Metab Res Rev. 2007;  23 625-630
    Google Scholar
  • 52 Lee T HKW, Benson J T, Therneau T M. et al . Serum aminotransferase activity and mortality risk in a United States community.  Hepatology. 2008;  47 880-887
    Google Scholar
  • 53 Stojakovic T SH, Trauner M, Pieske B. et al . Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography – The Ludwigshafen Risk and Cardiovascular Health Study.  Atherosclerosis. 2009;  [epub ahead of print]
    Google Scholar
  • 54 Haring R WH, Nauck M, Dorr M. et al . Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels.  Hepatology. 2009;  50 1403-1411
    Google Scholar
  • 55 Yun K ESC, Yoon Y S, Park H S. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans.  Atherosclerosis. 2009;  205 533-537
    Google Scholar
  • 56 Ruttmann E BL, Concin H, Diem G. et al . Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults.  Circulation. 2005;  112 2130-2137
    Google Scholar
  • 57 Strasak A MPR, Klenk J, Hilbe W. et al . Prospective study of the association of gamma-glutamyltransferase with cancer incidence in women.  Int J Cancer. 2008;  123 1902-1906
    Google Scholar
  • 58 Kazemi-Shirazi L EG, Winkler S, Schickbauer T. et al . Gamma glutamyltransferase and long-term survival: is it just the liver?.  Clin Chem. 2007;  53 940-946
    Google Scholar
  • 59 Mallat A, Hezode C, Lotersztajn S. Environmental factors as disease accelerators during chronic hepatitis C.  J Hepatol. 2008;  48 (4) 657-665
    Google Scholar
  • 60 El-Zayadi A R. Heavy smoking and liver.  World J Gastroenterol. 2006;  12 (38) 6098-6101
    Google Scholar
  • 61 Ishak K. et al . Histological grading and staging of chronic hepatitis.  J Hepatol. 1995;  22 (6) 696-699
    Google Scholar
  • 62 Desmet V J. et al . Classification of chronic hepatitis: diagnosis, grading and staging.  Hepatology. 1994;  19 (6) 1513-1520
    Google Scholar
  • 63 Liaw Y F. et al . Lamivudine for patients with chronic hepatitis B and advanced liver disease.  N Engl J Med. 2004;  351 (15) 1521-1531
    Google Scholar
  • 64 Schiff E. et al . Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.  Liver Transpl. 2007;  13 (3) 349-360
    Google Scholar
  • 65 Veldt B J. et al . Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.  Ann Intern Med. 2007;  147 (10) 677-684
    Google Scholar
  • 66 Mallet V. et al . Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C.  Ann Intern Med. 2008;  149 (6) 399-403
    Google Scholar
  • 67 Niederau C. et al . Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.  N Engl J Med. 1996;  334 (22) 1422-1427
    Google Scholar
  • 68 Kashi M R, Torres D M, Harrison S A. Current and emerging therapies in nonalcoholic fatty liver disease.  Semin Liver Dis. 2008;  28 (4) 396-406
    Google Scholar
  • 69 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.  Hepatology. 2009;  49 (1) 306-317
    Google Scholar
  • 70 Belfort R. et al . A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.  N Engl J Med. 2006;  355 (22) 2297-2307
    Google Scholar
  • 71 Ratziu V. et al . Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.  Gastroenterology. 2008;  135 (1) 100-110
    Google Scholar
  • 72 Manns M P, Strassburg C P. Autoimmune hepatitis: clinical challenges.  Gastroenterology. 2001;  120 (6) 1502-1517
    Google Scholar
  • 73 Manns M P, Woynarowski M BM. et al . Budesonide 3 mg TID is superior to Prednisolon in Combination with Azathioprine in the Treatment of Autoimmune Hepatitis.  J Hepatol. 2008;  48 (Suppl 2) 369
    Google Scholar
  • 74 Kirk A P. et al . Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis.  Gut. 1980;  21 (1) 78-83
    Google Scholar
  • 75 Niederau C. et al . Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis.  N Engl J Med. 1985;  313 (20) 1256-1262
    Google Scholar
  • 76 Smolarek C, Stremmel W. Therapy of Wilson disease.  Z Gastroenterol. 1999;  37 (4) 293-300
    Google Scholar
  • 77 Sroczynski G. et al . Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.  J Viral Hepat. 2009;  [epub ahead of print]
    Google Scholar
  • 78 Brady B SU, Sroczynski G. et al . Pegylated interferon combined with ribavirin for chronic hepatitis C virus infection: an economic evaluation (Technology Report No. 82).  Ottawa: Canadian Agency for Drugs and Technologies in Health. 2007; 
    Google Scholar
  • 79 Wright M. et al . Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.  Health Technol Assess. 2006;  10 (21) 1-113, iii
    Google Scholar
  • 80 Singer M E, Younossi Z M. Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults.  Am J Med. 2001;  111 (8) 614-621
    Google Scholar
  • 81 Toy M. et al . Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B.  Hepatology. 2009;  50 (3) 743-751
    Google Scholar
  • 82 Buti M. et al . Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.  J Hepatol. 2009;  51 (4) 640-646
    Google Scholar
  • 83 European Association For The Study Of The Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B.  J Hepatol. 2009;  50 (2) 227-242
    Google Scholar
  • 84 EASL Clinical Practice Guidelines: management of cholestatic liver diseases.  J Hepatol. 2009;  51 (2) 237-267
    Google Scholar
  • 85 Ghany M G. et al . Diagnosis, management, and treatment of hepatitis C: an update.  Hepatology. 2009;  49 (4) 1335-1374
    Google Scholar
  • 86 Marcellin P. et al . Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.  N Engl J Med. 2004;  351 (12) 1206-1217
    Google Scholar
  • 87 Bourliere M, Kahloun A, Gascou-Tessonnier G. Analogs and fibrosis regression in hepatitis B.  Gastroenterol Clin Biol. 2009;  33 (10 – 11) 923-929
    Google Scholar
  • 88 Schiff E. et al . Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.  Am J Gastroenterol. 2008;  103 (11) 2776-2783
    Google Scholar
  • 89 Poynard T. et al . Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.  Am J Gastroenterol. 2005;  100 (9) 1970-1980
    Google Scholar
  • 90 Lau G K. et al . Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.  N Engl J Med. 2005;  352 (26) 2682-2695
    Google Scholar
  • 91 Manns M P. et al . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358 (9286) 958-965
    Google Scholar
  • 92 McHutchison J G. et al . Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.  N Engl J Med. 1998;  339 (21) 1485-1492
    Google Scholar
  • 93 Fried M W. et al . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 (13) 975-982
    Google Scholar
  • 94 Di Bisceglie A M. et al . Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.  N Engl J Med. 2008;  359 (23) 2429-2441
    Google Scholar
  • 95 Suzuki A. et al . Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease.  J Hepatol. 2005;  43 (6) 1060-1066
    Google Scholar
  • 96 Hickman I J. et al . Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life.  Gut. 2004;  53 (3) 413-419
    Google Scholar
  • 97 Tock L. et al . Nonalcoholic fatty liver disease decrease in obese adolescents after multidisciplinary therapy.  Eur J Gastroenterol Hepatol. 2006;  18 (12) 1241-1245
    Google Scholar
  • 98 Milman N. et al . Clinically overt hereditary hemochromatosis in Denmark 1948 – 1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients.  Ann Hematol. 2001;  80 (12) 737-744
    Google Scholar
  • 99 Falize L. et al . Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases.  Hepatology. 2006;  44 (2) 472-477
    Google Scholar

Prof. Dr. Heiner Wedemeyer

Klinik für Gastroenterologie, Hepatologie and Endokrinologie, Medizinische Hochschule Hannover

Carl-Neuberg-Str. 1

30625 Hannover

Email: Wedemeyer.Heiner@mh-hannover.de

      >